Syros Prescription drugs Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Section 3 trial of tamibarotene didn’t meet its main endpoint of full response charge.
The trial assessed tamibarotene together with azacitidine in newly recognized higher-risk myelodysplastic syndrome (HR-MDS) sufferers with RARA gene overexpression.
Myelodysplastic syndrome is a uncommon blood most cancers that happens when the DNA in bone marrow stem cells is broken, stopping them from producing wholesome blood cells.
Within the first 190 enrolled sufferers, the entire response charge by intent-to-treat (ITT) within the tamibarotene/azacitidine therapy arm was 23.8% in comparison with 18.8% within the placebo/azacitidine management arm and was not statistically important (p-value = 0.2084).
Bristol Myers Squibb & Co BMY markets azacitidine as Vidaza.
Within the security evaluation of all enrolled sufferers (n=245), tamibarotene mixed with azacitidine (n=160) gave the impression to be usually well-tolerated, with an opposed occasion profile much like that seen in earlier Syros-sponsored research.
Syros additionally reported, as beforehand disclosed in its filings with the U.S. Securities and Change Fee (SEC), the failure of the SELECT-MDS-1 trial to attain its main endpoint constitutes an occasion of default below its secured mortgage facility with Oxford Finance.
“We’re deeply dissatisfied by this final result, significantly for the HR-MDS sufferers who’re looking for a brand new therapy choice for this difficult illness,” mentioned Conley Chee, CEO of Syros. “We plan to cease the research, evaluate the scientific knowledge extra completely and consider the following steps.”
In August, Syros Prescription drugs discontinued enrollment within the SELECT-AML-1 Section 2 trial, which evaluated a triplet routine of tamibarotene together with venetoclax and azacitidine in comparison with a doublet routine of venetoclax and azacitidine in newly recognized, unfit sufferers with acute myeloid leukemia (AML) and RARA gene overexpression.
The corporate mentioned the likelihood of the SELECT-AML-1 research’s success in demonstrating superiority within the last evaluation of 80 randomized sufferers was thought-about low.
SYRS Worth Motion: SYRS inventory is down 86.43% at 37 cents eventually test Wednesday.
Learn Subsequent:
Picture: Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
